{"classes":[{"categories":[{"measurements":[{"comment":"was not estimable due to insufficient number of events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"}],"units":"Participants"}],"description":"Progression free survival, defined as the time from the date of start of TFR to the date of event defined as the first occurrence of documented disease progression to Accelerated phase/Blast Crises (AP/BC) or the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"TFR is defined as no confirmed loss of MR4 (Molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \\> 0.01% IS. Loss of MMR does not require confirmation.","id":"OG000","title":"TFR Phase"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) included all patients who completed the consolidation phase successfully and entered the TFR phase.","reportingStatus":"POSTED","timeFrame":"nilotinib cessation up to approximately 580 weeks","title":"Progression Free Survival (PFS) After the Start of the TFR Phase","type":"SECONDARY","unitOfMeasure":"Weeks"}